Skip to content

Federal Contractor Profile

Illinois Institute Of Technology

$61M obligated·136 awards·5 agencies·17 NAICS

Federal Contracts

Showing award actions 51–100 of 188 funded award actions, most recent first.

Contracts with positive obligations
136
Funded award actions shown
188
Obligations shown
$61M
Awarding agencies
5

This table shows award actions with a positive obligation. Zero-dollar and negative-dollar actions, such as administrative changes and deobligations, are not displayed. Multiple award actions may belong to the same contract.

Award data as of September 28, 2026. Source: USAspending federal award records.

DateAgencyPIIDNAICSDescriptionAmount
Feb 20, 2024Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA75N95020F00001541712NON-CLINICAL SAFETY OF PTH-1A, INVERSE AGONIST, TO SUPPORT JANSEN METAPHYSEAL CHONDRODYSPLASIA (JMC) DISEASE. POP: 09/16/2020 TO 03/15/2020.$21K
Feb 2, 2024Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA75N95020F00001541712NON-CLINICAL SAFETY OF PTH-1A, INVERSE AGONIST, TO SUPPORT JANSEN METAPHYSEAL CHONDRODYSPLASIA (JMC) DISEASE. POP: 09/16/2020 TO 03/15/2020.$59K
Jan 3, 2024Department of Health and Human ServicesNIH NCI75N91018F00005541711IGF::OT::IGF LFA-9 (MPGES-1/5-LOX INHIBITOR): PRECLINICAL STUDIES TO SUPPORT A CLINICAL TRIAL, POP 9/17/18-9/16/2020 (UP TO 9/17/2021 IF ALL OPTIONAL TASKS EXERCISED)$39K
Sep 18, 2023Department of Health and Human ServicesNIH NCI75N91023F00001541714BASE TITLE: PREVENT PRECLINICAL PHARMACOLOGY AND TOXICOLOGY TASK ORDER TITLE: NICOTINE REDUCTION THERAPY USING THE HUMAN MONOCLONAL ANTIBODY ATI-1013$659K
Sep 14, 2023Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA75N95020F00003541712NON-CLINICAL SAFETY ASSESSMENT OF DRINABANT, A CANNABINOID RECEPTOR (CB-1) ANTAGONIST, FOR ACUTE CANNABINOID OVERDOSE (ACO). POP: 09/25/2020 TO 03/24/2021.$1.4M
Aug 9, 2023Department of Health and Human ServicesNIH NCI75N91022C00010541715PRECLINICAL TOXICOLOGY OF LARGE MOLECULE DRUGS DEVELOPED FOR CANCER AND OTHER INDICATIONS$677K
Jun 30, 2023Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA75N95020F00001541712NON-CLINICAL SAFETY OF PTH-1A, INVERSE AGONIST, TO SUPPORT JANSEN METAPHYSEAL CHONDRODYSPLASIA (JMC) DISEASE. POP: 09/16/2020 TO 03/15/2020.$202K
Jun 29, 2023Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA75N95020F00002541712TASK ORDER TITLE: NON-CLINICAL SAFETY OF MITRAGYNINE TO SUPPORT ITS FUTURE ORAL THERAPY FOR ANALGESIA INDICATION. POP: 09/17/2020 TO 03/16/2022.$224K
Jun 29, 2023Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA75N95022F00001541712NON-CLINICAL SAFETY ASSESSMENT OF COVALENT BI-TOX TO SUPPORT NEUROPATHIC PAIN INDICATION$22K
Mar 28, 2023Department of Health and Human ServicesNIH NCI75N91020F00001541714TASK ORDER: TOPICAL RESATORVID FOR NONMELANOMA SKIN CANCER PREVENTION PERIOD OF PERFORMANCE: 09/21/2020 - 03/20/2022$645K
Mar 23, 2023Department of Health and Human ServicesNIH NCI75N91022C00010541715PRECLINICAL TOXICOLOGY OF LARGE MOLECULE DRUGS DEVELOPED FOR CANCER AND OTHER INDICATIONS$309K
Mar 2, 2023Department of Health and Human ServicesNIH NCI75N91022C00010541715PRECLINICAL TOXICOLOGY OF LARGE MOLECULE DRUGS DEVELOPED FOR CANCER AND OTHER INDICATIONS$471K
Feb 22, 2023Department of Health and Human ServicesNIH NCI75N91018F00005541711IGF::OT::IGF LFA-9 (MPGES-1/5-LOX INHIBITOR): PRECLINICAL STUDIES TO SUPPORT A CLINICAL TRIAL, POP 9/17/18-9/16/2020 (UP TO 9/17/2021 IF ALL OPTIONAL TASKS EXERCISED)$419K
Nov 14, 2022Department of DefenseNROTCU ILLINOIS INST OF TECHNOLOGYN6321523F0011611310TUTION AND FEES FOR FALL 2021$301K
Sep 23, 2022Department of Health and Human ServicesNIH NCI75N91022F00001541715CONTRACT ORIENTATION & KICKOFF MEETING FOR R&D SERVICES UNDER "PRECLINICAL TOXICOLOGY OF SMALL MOLECULE DRUGS DEVELOPED FOR CANCER AND OTHER INDICATIONS"$3K
Sep 22, 2022Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA75N95022F00001541712NON-CLINICAL SAFETY ASSESSMENT OF COVALENT BI-TOX TO SUPPORT NEUROPATHIC PAIN INDICATION$744K
Jul 15, 2022Department of Health and Human ServicesNIH NCI75N91020F00001541714TASK ORDER: TOPICAL RESATORVID FOR NONMELANOMA SKIN CANCER PREVENTION PERIOD OF PERFORMANCE: 09/21/2020 - 03/20/2022$123K
Jun 22, 2022Department of Health and Human ServicesNIH NCI75N91022C00010541715PRECLINICAL TOXICOLOGY OF LARGE MOLECULE DRUGS DEVELOPED FOR CANCER AND OTHER INDICATIONS$675K
May 15, 2022Department of DefenseNROTCU ILLINOIS INST OF TECHNOLOGYN6321522F0010611310TUITION AND FEES FOR 2022 SPRING SEMESTER$341K
May 4, 2022Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA75N95020F00001541712NON-CLINICAL SAFETY OF PTH-1A, INVERSE AGONIST, TO SUPPORT JANSEN METAPHYSEAL CHONDRODYSPLASIA (JMC) DISEASE. POP: 09/16/2020 TO 03/15/2020.$698K
Apr 26, 2022Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA75N95020F00002541712TASK ORDER TITLE: NON-CLINICAL SAFETY OF MITRAGYNINE TO SUPPORT ITS FUTURE ORAL THERAPY FOR ANALGESIA INDICATION. POP: 09/17/2020 TO 03/16/2022.$207K
Mar 29, 2022Department of Health and Human ServicesNIH NCI75N91022C00010541715PRECLINICAL TOXICOLOGY OF LARGE MOLECULE DRUGS DEVELOPED FOR CANCER AND OTHER INDICATIONS$75K
Mar 28, 2022Department of Health and Human ServicesNIH NCI75N91020F00001541714PREVENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS; TASK ORDER TITLE: PRECLINICAL DEVELOPMENT OF AN RNA VACCINE FOR IMMUNOPREVENTION OF PROSTATE CANCER$291K
Feb 14, 2022Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA75N95020F00003541712NON-CLINICAL SAFETY ASSESSMENT OF DRINABANT, A CANNABINOID RECEPTOR (CB-1) ANTAGONIST, FOR ACUTE CANNABINOID OVERDOSE (ACO). POP: 09/25/2020 TO 03/24/2021.$10K
Dec 14, 2021Department of DefenseNROTCU ILLINOIS INST OF TECHNOLOGYN6321522F0003611310TUTION AND FEES FOR FALL 2021$353K
Dec 10, 2021Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID75N93022F00001541714PRECLINICAL MICROBIOLOGICAL, SAFETY, TOXICOLOGY, AND PHARMACOKINETIC SERVICES$1.9M
Dec 3, 2021Department of Health and Human ServicesNIH NCI75N91020F00001541714TASK ORDER: TOPICAL RESATORVID FOR NONMELANOMA SKIN CANCER PREVENTION PERIOD OF PERFORMANCE: 09/21/2020 - 03/20/2022$34K
Sep 30, 2021Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA75N95021F00001541715CONTRACT KICK-OFF MEETING FOR NINDS PHARMACOLOGY AND TOXICOLOGY FOR THERAPEUTICS PROGRAM (PTTP)$11
Sep 29, 2021Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA75N95021F00001541715CONTRACT KICK-OFF MEETING FOR NINDS PHARMACOLOGY AND TOXICOLOGY FOR THERAPEUTICS PROGRAM (PTTP)$2K
Sep 7, 2021Department of Health and Human ServicesNIH NCI75N91018F00005541711IGF::OT::IGF LFA-9 (MPGES-1/5-LOX INHIBITOR): PRECLINICAL STUDIES TO SUPPORT A CLINICAL TRIAL, POP 9/17/18-9/16/2020 (UP TO 9/17/2021 IF ALL OPTIONAL TASKS EXERCISED)$702K
Aug 23, 2021Department of Health and Human ServicesNIH NCI75N91021F00001541714EVALUATION OF AFPEP FOR THE PREVENTION OF BREAST CANCER$535K
Jul 19, 2021Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA75N95020F00001541712NON-CLINICAL SAFETY OF PTH-1A, INVERSE AGONIST, TO SUPPORT JANSEN METAPHYSEAL CHONDRODYSPLASIA (JMC) DISEASE. POP: 09/16/2020 TO 03/15/2020.$1.3M
Jun 23, 2021Department of Health and Human ServicesNIH NCI75N91018F00005541711IGF::OT::IGF LFA-9 (MPGES-1/5-LOX INHIBITOR): PRECLINICAL STUDIES TO SUPPORT A CLINICAL TRIAL, POP 9/17/18-9/16/2020 (UP TO 9/17/2021 IF ALL OPTIONAL TASKS EXERCISED)$25K
Jun 9, 2021Department of DefenseNROTCU ILLINOIS INST OF TECHNOLOGYN6321521F0401611310TUITION AND FEES FOR SPRING SEMESTER AT ILLINOIS INSTITUTE OF TECHNOLOGY$222K
Apr 27, 2021Department of Health and Human ServicesNIH NCI75N91018F00005541711IGF::OT::IGF LFA-9 (MPGES-1/5-LOX INHIBITOR): PRECLINICAL STUDIES TO SUPPORT A CLINICAL TRIAL, POP 9/17/18-9/16/2020 (UP TO 9/17/2021 IF ALL OPTIONAL TASKS EXERCISED)$118K
Feb 26, 2021Department of Health and Human ServicesNIH NCIHHSN26100003541690IGF::OT::IGF NEXT PRECLINICAL TOXICOLOGY&PHARMACOLOGY OF DRUGS DEVELOPED FOR CANCER PATIENTS, TO#3, EXPLORATORY STUDIES OF CCR4 CART CELLS$239K
Feb 11, 2021Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA75N95020F00001541712NON-CLINICAL SAFETY OF PTH-1A, INVERSE AGONIST, TO SUPPORT JANSEN METAPHYSEAL CHONDRODYSPLASIA (JMC) DISEASE. POP: 09/16/2020 TO 03/15/2020.$530K
Dec 8, 2020Department of DefenseNROTCU ILLINOIS INST OF TECHNOLOGYN6321521F0400611310TUTION AND FEES FOR FALL 2019$217K
Nov 30, 2020Department of DefenseW6QK ACC-APG NATICKW911QY21C0014541380TECHNLOLOGY TRANSFER ASSAYS$981K
Sep 24, 2020Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA75N95020F00003541712NON-CLINICAL SAFETY ASSESSMENT OF DRINABANT, A CANNABINOID RECEPTOR (CB-1) ANTAGONIST, FOR ACUTE CANNABINOID OVERDOSE (ACO). POP: 09/25/2020 TO 03/24/2021.$324K
Sep 21, 2020Department of Health and Human ServicesNIH NCI75N91020F00001541690SUPPORT FOR THE PRECLINICAL DEVELOPMENT OF EIF4A INHIBITORS ROCAGLAMIDE AND DIDESMETHYLROCAGLAMIDE. (TOXICIOLOGY SERVICES TO SUPPORT PRECLINICAL DRUG DEVELOPMENT) POP 09/23/2020-09/22/2021.$589K
Sep 16, 2020Department of Health and Human ServicesNIH NCI75N91020F00002541714COVID-19 RELATED STUDY INVOLVING DOGS$598K
Sep 16, 2020Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA75N95020F00002541712TASK ORDER TITLE: NON-CLINICAL SAFETY OF MITRAGYNINE TO SUPPORT ITS FUTURE ORAL THERAPY FOR ANALGESIA INDICATION. POP: 09/17/2020 TO 03/16/2022.$1.8M
Sep 15, 2020Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA75N95020F00001541712NON-CLINICAL SAFETY OF PTH-1A, INVERSE AGONIST, TO SUPPORT JANSEN METAPHYSEAL CHONDRODYSPLASIA (JMC) DISEASE. POP: 09/16/2020 TO 03/15/2020.$153K
Sep 14, 2020Department of Health and Human ServicesNIH NCI75N91020F00001541714TASK ORDER: TOPICAL RESATORVID FOR NONMELANOMA SKIN CANCER PREVENTION PERIOD OF PERFORMANCE: 09/21/2020 - 03/20/2022$213K
Sep 2, 2020Department of Health and Human ServicesNIH NCI75N91020F00001541714PREVENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS; TASK ORDER TITLE: PRECLINICAL DEVELOPMENT OF AN RNA VACCINE FOR IMMUNOPREVENTION OF PROSTATE CANCER$430K
Aug 27, 2020Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA75N95019F00091541712NON-CLINICAL SAFETY ASSESSMENT OF ACOZIBOROLE (SCYX-7158) TO SUPPORT HUMAN AFRICAN TRYPANOSOMIASIS (HAT OR "SLEEPING SICKNESS"). POP: 09/01/2019 TO 08/31/2020.$7K
Aug 26, 2020Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDAHHSN27100001541712IGF::OT::IGF TASK ORDER AWARD FOR "NON-CLINICAL SAFETY ASSESSMENT OF SPIF TO SUPPORT CHRONIC GVHD INDICATION" TO IIT RESEARCH INSTITUTE$95K
Jul 17, 2020Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA75N95019F00091541712NON-CLINICAL SAFETY ASSESSMENT OF ACOZIBOROLE (SCYX-7158) TO SUPPORT HUMAN AFRICAN TRYPANOSOMIASIS (HAT OR "SLEEPING SICKNESS"). POP: 09/01/2019 TO 08/31/2020.$81K
Jun 3, 2020Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA75N95019F00090541712GLP 28 DAY TOXICITY STUDY OF ACT-1 WHEN APPLIED TOPICALLY TO EYES TWICE DAILY FOR 28 DAYS IN DOGS WITH A 14 DAY RECOVERY PERIOD. POP: 09/01/2019 TO 02/29/2020.$85K

Get Alerted Before Illinois Institute Of Technology's Next Recompete

Mindy monitors active contracts and flags recompetes 12 months out so you can position to compete.

Start for free